Search results
Showing 1786 to 1800 of 1991 results for nice guidelines
Engage at the optimal time for your technology appraisal, to achieve NICE guidance at the same time as marketing authorisation.
Evidence-based recommendations on efanesoctocog alfa (Altuvoct) for treating and preventing bleeding episodes in haemophilia A in people 2 years and over.
NICE has a key role in UK licensing and the evaluation of and access to new and innovative products for the health system.
NICE's guidance executive is made up of executive directors, guidance centre directors and senior team members.
Day-to-day decision making is the responsibility of NICE's executive team.
Home What NICE does Digital health...
Our first guideline on kidney cancer recommends better use of biopsies to avoid surgery
New guidance aims to reduce variation in treatment and prevent unnecessary surgery, improving care for patients and supporting healthcare professionals.
"position":2,"item":{"@id":"/about-us","name":"About us"}}]} Structure of NICE NICE is an organisation made up of people...
Learn from NICE International, part of the UK's National Institute for Health and Care Excellence, about how to improve your nation's health and wellbeing
First NICE-curated guideline announced ahead of World Duchenne Awareness Day
In the lead-up to World Duchenne Awareness Day on Sunday 7 September, we’re pleased to announce the completion of our first assessment of an externally developed clinical guideline.
Our modular updates framework ensures flexibility and consistency in updating our manuals and helps prioritise important updates.
We assess the efficacy and safety of interventional procedures used for treatment or diagnosis to determine whether they work well enough and are safe enough for use in the NHS.
NICE wants as many people as possible to be able to use our services, and we have designed it to be accessible.
The guidance development timeline
Biggest shake-up in type 2 diabetes care in a decade announced
Millions of people are set to benefit from earlier access to newer type 2 diabetes treatments – the biggest shake-up in care for a decade – as part of NICE’s commitment to re-evaluate priority clinical pathways described in the 10-Year Health Plan for the NHS.